Investival ShowcaseMonday, 16 November 2026 - GMT (Greenwich Mean Time, GMTZ)

Digital health funding has fundamentally reset. Investors are now far more selective about where capital flows, with new criteria for what makes companies fundable. This panel brings together active investors and recently funded founders to discuss which business models, clinical areas, and metrics are driving investment decisions today—and where the next wave of opportunity lies

• What business models are getting funded now and what's fallen out of favour?

• Clinical areas and patient populations where investors see sustainable unit economics

• The metrics and milestones investors require before writing checks at each funding stage

• Emerging categories and underinvested opportunities where capital is starting to flow

For years, AI in drug discovery dominated the techbio conversation. But the real transformation is happening across the entire value chain—from target identification to clinical trial design, manufacturing optimization, and patient stratification. The question is no longer whether technology belongs in life sciences, but how fast we can deploy it everywhere it matters. This panel brings together investors to explore what's working, what's overhyped, and where the white space opportunities still exist. With capital becoming more specialized and expectations rising, understanding the full landscape—from funding dynamics to practical implementation challenges—is critical for anyone building or backing the next generation of data-driven life sciences companies

• Evaluating the main challenges, investment landscape and opportunities in the space

• Are there enough specialist investors to help support, nurture and grow TechBio companies?

• Moving from just AI in drug discovery – How can we use tech across the whole drug value chain?

• Perspectives from Big Pharma – What are they looking for from TechBio companies?